Goldman Urology Clinic recently achieved 6,000 cases of benign prostatic hyperplasia (BPH) surgery, thereby demonstrating its robust treatment capabilities. The explanation is that the meticulous analysis of each patient's condition and the application of optimal surgical techniques have led to these impressive clinical outcomes.
Benign prostatic hyperplasia (BPH) is known as a common disease among middle-aged and elderly men. It is characterized by the prostate gland becoming excessively enlarged and compressing the urethra, leading to lower urinary tract symptoms (LUTS) such as frequent urination, nocturia (nighttime urination), a feeling of incomplete bladder emptying (residual urine sensation), and delayed urination. In the early stages of BPH, symptoms can be managed with medication. However, if the response to medication decreases or symptoms recur and worsen, surgical treatment becomes necessary. At this point, it is crucial to comprehensively consider not only the size and shape of the prostate but also the symptoms, presence of complications, existence of chronic diseases, anesthesia conditions, and recovery plan, to guide the patient in selecting the most appropriate surgical technique.
In accordance with these treatment principles, Goldman Urology Clinic has strived to introduce the latest surgical techniques and refine its clinical protocols. This includes expanding the spectrum of available treatments based on the patient's condition, such as the Rezum procedure, which injects high-temperature steam to necrotize and shrink hypertrophied tissue; Aquablation (Waterjet Robotic Surgery), which uses a high-pressure AI robot waterjet to precisely resect prostatic tissue without thermal damage; and HoLEP (Holmium Laser Enucleation of the Prostate) surgery, which completely removes hypertrophied tissue using a holmium laser.
Furthermore, by simultaneously operating various methods such as iTind, which widens the prostatic urethra, and UroLift, which minimizes the burden of surgical resection, the clinic has established customized treatment strategies based on the patient's prostate size, shape, and symptom severity.
Moreover, Goldman Urology Clinic has been continuously conducting research on BPH, based on over 2 million clinical data points accumulated over more than 20 years. These research achievements are accumulated as clinical outcomes in actual medical practice, leading to positive evaluations. In fact, based on its clinical experience with waterjet robotic surgery, the clinic has presented relevant research findings at academic conferences and has verified and complemented the safety and efficacy of the latest surgical techniques in real clinical settings.
Dr. Lee Chang-ki, the chief representative director of Goldman Urology Clinic, stated, "The outcomes of BPH surgery inevitably vary depending on the medical staff's proficiency, the accuracy of pre-operative evaluation, and the post-operative management system. The medical staff across all branches of Goldman Urology Clinic has enhanced treatment consistency and stability through a system that periodically shares clinical data and collectively develops treatment protocols." He added, "Especially for BPH, since each patient experiences discomfort differently, and concomitant diseases or recovery plans also vary, our core principle is an approach that offers the necessary surgical technique at the time it is needed for the patient, rather than fixing on one method as the sole correct answer."